INSYS Therapeutics Names New General Counsel
10 oct. 2018 06h00 HE
|
INSYS Therapeutics, Inc.
PHOENIX, Oct. 10, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
INSYS Therapeutics Signs Definitive License Agreement with Lunatus to Commercialize SUBSYS® (fentanyl sublingual spray) in the Middle East
01 oct. 2018 06h00 HE
|
INSYS Therapeutics, Inc.
PHOENIX, Oct. 01, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
INSYS Therapeutics to Present at 2018 Cantor Global Healthcare Conference
27 sept. 2018 18h53 HE
|
INSYS Therapeutics, Inc.
PHOENIX, Sept. 27, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
INSYS Therapeutics Completes Initial Clinical Study of Dronabinol Inhalation with Innovative Breath-Actuated Inhaler
24 sept. 2018 06h00 HE
|
INSYS Therapeutics, Inc.
PHOENIX, Sept. 24, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
INSYS Therapeutics to Present at Janney Healthcare Conference
14 sept. 2018 14h00 HE
|
INSYS Therapeutics, Inc.
PHOENIX, Sept. 14, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
INSYS Therapeutics and UC San Diego’s Center for Medicinal Cannabis Research Expand Collaboration to Include Clinical Study of Cannabidiol in Early Psychosis
04 sept. 2018 06h00 HE
|
INSYS Therapeutics, Inc.
PHOENIX, Sept. 04, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
FDA Grants INSYS Therapeutics ‘Fast Track’ Designation for Epinephrine Nasal Spray as Investigational Treatment for Anaphylaxis
30 août 2018 06h00 HE
|
INSYS Therapeutics, Inc.
PHOENIX, Aug. 30, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
INSYS Therapeutics Appoints Elizabeth Bohlen to Board of Directors
09 août 2018 07h00 HE
|
INSYS Therapeutics, Inc.
PHOENIX, Aug. 09, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...
INSYS Therapeutics Reports Second Quarter 2018 Results
08 août 2018 16h15 HE
|
INSYS Therapeutics, Inc.
PHOENIX, Aug. 08, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids (CBD) and spray...
INSYS Therapeutics Reaches Agreement in Principle to Settle Department of Justice Investigation
08 août 2018 07h00 HE
|
INSYS Therapeutics, Inc.
PHOENIX, Aug. 08, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray...